ELIL J3L-MC-EZEJ Lp(a) CCTA (ELS)

About this study:

This study is for people who have high levels of lipoprotein(a), also called Lp(a), a type of cholesterol in the blood that can increase the risk of heart disease. Researchers are studying whether a medication called lepodisiran can lower Lp(a) and help reduce harmful buildup (plaque) in the heart’s blood vessels.

You may qualify if:

• Your Lp(a) is high (≥175)

• You have heart disease or are at high risk for it
• A heart scan (CCTA) shows plaque in your arteries
• Your cholesterol medications have been stable for at least 8 weeks

You may NOT qualify if:

• You had a recent heart attack or stroke (within 60 days)

• You have serious kidney or heart failure
• You’ve had bypass surgery (CABG)
• You’re planning a heart procedure soon (stent, surgery, etc.)
• You’ve received special treatments to lower Lp(a)
• You can’t safely undergo a CT scan (contrast allergy, etc.)

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable) )

Study Details: 

Location: Jacksonville, FL 

All study-related care is provided at no cost to you or your insurance company.

About this study: 

This extension study looks at the long-term safety and effectiveness of remibrutinib in people with CSU(Chronic Spontaneous Uticaria“Hives”   who completed a prior study, while also allowing continued access to the medication after the Phase 3 studies, when appropriate.

Who can join:

• You must sign a consent form before any study procedures.

• You must be 18 years or older.
• You must have completed a previous remibrutinib study.
• You should be willing and able to follow the study visits and instructions.

Who cannot join:

• You have a high risk of bleeding or a bleeding disorder.

• You have a history of stomach or intestinal bleeding.
• You need to take blood thinners or medications that affect clotting.
• You have current or past liver disease.
• You have other serious health conditions (such as heart, lung, kidney, immune, or mental health conditions) that could make participation unsafe or affect study results.

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable) )

Study Details: 

Location: Jacksonville, FL 

All study-related care is provided at no cost to you or your insurance company.

About this study: 

This study is testing how well new medicines (CagriSema and cagrilintide) help children and teens lose weight.

Who can join?

• Ages 8 to under 18

• Higher body weight for age/height
• Tried diet and exercise for 3+ months without enough success
• Weigh over 45 kg (99 lbs)
• Parent/guardian consent + child agreement
• Normal lab tests

If they have type 2 diabetes:

• Controlled blood sugar

• Only on lifestyle changes or stable metformin

Who cannot join?

• Used weight-loss meds in last 90 days

• Had recent weight-loss surgery/devices

• Uncontrolled thyroidor genetic/hormonal obesity
• Big weight change(>5%) in last 3 months
• Type 1 diabetes

Extra exclusions:

• Without T2D: high blood sugar or diabetes meds

• With T2D: frequent low blood sugar, certain antibodies, other diabetes meds, or serious eye problems

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable) )

Study Details: 

Location: Jacksonville, FL 

All study-related care is provided at no cost to you or your insurance company.

NOVO-NN9490-8027 AMAZE 7 Obesity

About this Study:

The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.

Inclusion Criteria:

1. Body mass index (BMI) at screening ≥ 30.0 kg/m2.
2. Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed:
   1. Liposuction and/or abdominoplasty, if performed > 1 year before screening
   2. Adjustable gastric banding, if the band has been removed > 1 year before screening
   3. Intragastric balloon, if the balloon has been removed > 1 year before screening
   4. Duodenal-jejunal bypass liner (e.g. Endobarrier), if the sleeve has been removed > 1 year before screening
   5. Non-pharmaceutical, non-invasive, biodegradable devices, if last used > 1 year before screening

Exclusion Criteria:

• Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
• History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
• Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.

Why participate?

• Help advance research in heart disease prevention

• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

NOVO-NN9487-8023 Obesity AMAZE 9

About this Study: 

A research study designed to learn more about how effective zenagamtide tablets may be in helping people who are overweight achieve meaningful weight loss.

Key Inclusion Criteria:

• Age 18-69 years (both inclusive) at the time of signing the informed consent.
• Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed if the procedure and removal of the device was uncomplicated:
  1. Liposuction and/or abdominoplasty, if performed > 1 year before screening
  2. Adjustable gastric banding, if the band has been removed > 1 year before screening
  3. Intragastric balloon, if the balloon has been removed > 1 year before screening
  4. Duodenal-jejunal bypass liner (e.g. Endobarrier), if the sleeve has been removed > 1 year before screening
  5. Non-pharmaceutical, non-invasive, biodegradable devices, if last used > 1 year before screening

Key Exclusion Criteria:

• HbA ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening
• History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records
• Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues within 1 year before screening

Why participate?

• Help advance research in heart disease prevention

• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

PFI C6491015 VESPER SWITCH Obesity 

About this study

The study aims to learn more about weight management and health outcomes in adults who have been consistently taking wright loss medications.

Who May Be Able to Participate?

You may qualify if:

• You are 18 years of age or older (or the minimum age required by local regulations).
• You have been taking:
  • Semaglutide (Wegovy®) 1.7 mg or 2.4 mg once weekly for at least 6 months, with no dose changes in the last 90 days, or
  • Tirzepatide (Zepbound®) 5 mg, 10 mg, or 15 mg once weekly for at least 6 months, with no dose changes in the last 90 days.
• You have generally taken your medication as prescribed. Up to 3 missed doses in the past 6 months may be allowed if they were missed because of a medical procedure or hospitalization.
• You meet any reproductive health requirements reviewed by the study team.

Who Cannot Participate?

You may not qualify if any of the following apply to you:

Weight-Related Conditions

• Your Body Mass Index (BMI) is less than 25 kg/m² at the screening visit.
• You have had or are planning to have weight-loss surgery.
  • Liposuction or tummy tuck procedures performed more than 1 year ago are allowed.
• You have had, currently have, or plan to have certain weight-loss devices or procedures, such as:
  • Gastric balloon
  • Gastric artery embolization
  • Duodenal-jejunal bypass sleeve
  • Other similar obesity treatments
• Your obesity is caused by certain hormonal or genetic conditions, such as:
  • Cushing’s syndrome
  • MC4R (Melanocortin 4 Receptor) deficiency
  • Prader-Willi syndrome

Diabetes and Hormone-Related Conditions

• You have a history of diabetes.
• Your screening laboratory results suggest that you have diabetes.

Why participate?

• Help advance research in heart disease prevention

• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

GSK 218130 Flu Vax Age 65+

About this study:

The purpose of this study is to learn how safe and effective an investigational influenza (flu) vaccine is in adults 65 years of age and older.

Basic Eligibility:

To participate, you must:

• Be 65 years of age or older at the time you receive the study vaccine.
• Not have had a confirmed influenza infection within the past 180 days.

The study team will review your medical history and current health to determine whether the study is a good fit for you.

Why participate?

•  Help advance research in heart disease prevention
• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

GSK 218130 Flu Vax Age 65+

About this study:

The purpose of this study is to learn how safe and effective an investigational influenza (flu) vaccine is in adults 65 years of age and older.

Basic Eligibility:

To participate, you must:

• Be 65 years of age or older at the time you receive the study vaccine.
• Not have had a confirmed influenza infection within the past 180 days.

The study team will review your medical history and current health to determine whether the study is a good fit for you.

Why participate?

•  Help advance research in heart disease prevention
• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.